Lack Of Supplement NDI Notification Guidance Not A Market Pass For Industry
This article was originally published in The Rose Sheet
Manufacturers, ingredient suppliers and other parties submitting NDI notifications can improve the industry's outlook by "anticipating future products that haven't been brought to market yet" and proposing the highest concentration of an ingredient for the broadest variety of uses, says ODSP senior advisory Cara Welch.
You may also be interested in...
FDA ODSP details “data, research results, and other information” it needs on NAC that could sway proposing a rulemaking to allow its continued use in supplements. One detail missing is what the agency’s asking for are NDI notifications for NAC.
Stacy Cline Amin expects publication in “near future” of draft guidance on FDA’s NDI notification requirement, a document the agency says it expects to provide within a year. Amin, now with Morrison & Foerster as partner in Washington, also acknowledged FDA’s predicament with regulating products containing cannabinoids.
In comments on VMS industry oversight, PhRMA recommends FDA adhere to clear regulations that determine whether substances are eligible for use as dietary ingredients. DSHEA makes clear that some dietary ingredients are not eligible for use VMS products.